[ad_1]
SEATTLE – (BUSINESS WIRE– According to Coherent Market Insights, the typhoid vaccine market
has been valued at USD 225.0 million in 2018 and is expected to
CAGR of 11.9% over the forecast period (2018-2026).
Key Trends and Market Analysis for Typhoid Vaccine:
Organizations such as the World Health Organization (WHO), Gavi, Bill &
Melinda Gates Foundation, and others are very active in the spread
awareness of diseases such as typhoid and the immunization of drivers
efforts against these diseases. Such initiatives from various organizations
should support and fuel the growth of the global typhoid vaccine market
over the forecast period.
Request a copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/2552
For example, in October 2017, WHO recommended the introduction of typhoid
vaccine for children over six months in endemic countries. This too
recommended catch-up vaccination as much as possible, giving priority
children and teens up to 15 years old.
For example, in April 2018, Gavi designated $ 85 million to fund
introduction of Typbar TCV vaccine (Bharat Biotech) in low-income countries
countries in Africa and Asia. In addition, there are several
typhoid conjugate vaccines in the pipeline, which should be
enter the market during the forecast period. Such initiatives taken by
these organizations should dramatically increase the adoption of typhoid
and stimulate the growth of the global market for typhoid vaccine during
forecast period.
In addition, the introduction of clinically effective typhoid vaccines
in private markets (such as India) and internationally.
supported the growth of the market. For example, Vivotif (oral vaccine),
Typhim Vi clinically more effective (prequalified by WHO in 2011), and now
TCV Typbar (WHO's first prequalified conjugate vaccine in 2017) is now
available in the same market, including India and South Africa.
To know the latest trends and knowledge prevailing in this market,
click on the link below:
https://www.coherentmarketinsights.com/market-insight/typhoid-fever-vaccines-market-2552
Points to remember in the market:
-
The market is expected to have a CAGR of 11.9% over the forecast period.
period (2018-2026). This growth is attributed to the rise in
various organizations to increase access to typhoid vaccines
endemic areas and new product launches in the region -
The typhoid vaccine market in Asia-Pacific is expected to represent
the largest market share during the forecast period, due to
incidence of typhoid fever and presence of the established vaccine
manufacturers. -
Typhoid Vaccine Market in North America Should Show
stagnant growth, as the prevalence of typhoid fever is much lower
US and typhoid vaccines are not recommended for routine treatment.
vaccinations in the United States and Canada. -
Typhoid vaccine market in Europe is expected to average
growth during the forecast period, due to the low prevalence of typhoid in
Region. For example, according to data published by European
Center for Disease Prevention and Control, in 2014, approximately 934
Confirmed cases of typhoid / paratyphoid fever have been reported in 27 EU / EEA countries
with an EU / EEA notification rate of 0.31 cases per year.
100,000 inhabitants. -
Various key players are involved in strategic collaborations and
research and development activities for the development and commercialization of
new typhoid vaccine. For example, in 2018, Prokarium Limited, a
A UK-based vaccine developer has secured $ 10 million in funding
various Saudi, Swedish and Korean investors for the development of new
revolutionary vaccines against enteric fever, including typhoid. -
The main market players are participating in a strategic partnership for
distribution of its products. For example, in 2015, PaxVax, Inc.,
concluded in various commercial partnerships and distribution agreements
to increase the availability of Vivotif in the European region. For
For example, Valneva SE and PaxVax, Inc. have entered into a marketing agreement and
distribution agreement in 2015 for their respective travel vaccines,
DUKORAL and Vivotif -
Some of the main players in global typhoid fever
The vaccine market includes GlaxoSmithKline Plc., Sanofi SA, Bharat
Biotech, Bio-Med Pvt. Ltd., PT Bio Farma, Shanghai PaxVax, Inc.
Institute of Organic Products SA, and Prokarium
Source link
